SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
Innovative Science Overcomes Formulation Challenges
SRI has patented a novel approach to vaccine delivery that is safe for pediatric use, eliminating the need for painful injections.
A new oral version of a known chelating agent can defend against mass radiation exposure in a terrorist attack.
Partnering to Advance Therapy for Radiation Exposure
Vitamin A deficiency causes susceptibility — especially in children — to diarrhea-causing infections, which lead to millions of deaths each year. SRI is developing a probiotic that produces the vitamin.